key: cord-0848200-la1bbues
authors: Mo, A.; Chung, J.; Eichler, J.; Yukelis, S.; Feldman, S.; Fox, J. L.; Garg, M. K.; Kalnicki, S.; Ohri, N.; Sparano, J. A.; Klein, J.
title: Breast Cancer Survivorship Care During the COVID-19 Pandemic Within an Urban New York Hospital System
date: 2021-11-01
journal: International Journal of Radiation Oncology*Biology*Physics
DOI: 10.1016/j.ijrobp.2021.07.651
sha: 2434c3b12ec4b1aeec7cb444052779a23d9f1d30
doc_id: 848200
cord_uid: la1bbues

Purpose/Objective(s) The COVID-19 pandemic has placed a tremendous burden on healthcare systems and has forced oncology providers and cancer patients to balance pandemic risks with maintaining standard cancer survivorship care. We evaluated adherence to long-term follow-up among early-stage breast cancer patients in an urban, academic cancer center in the New York City borough of The Bronx during the COVID-19 pandemic. Materials/Methods We retrospectively reviewed patients with stage I-II breast cancer who underwent resection and adjuvant therapy at our center. Adherence with long-term follow-up was evaluated based on contact with any oncology specialist (surgical, medical, or radiation) at our center between two and five years after breast cancer surgery. Patients were deemed adherent to follow-up during COVID-19 if they attended an oncology follow-up appointment (in-person or telemedicine) between March 1 and December 1, 2020; patients were deemed non-adherent if they attended follow-up during the same date range in 2019, prior to the pandemic, but did not follow-up during the COVID-19 period. Adherence during COVID-19 was compared with pre-COVID rates of follow-up. Clinical and demographic data were evaluated as potential predictors of adherence. Local COVID-19 case rates were estimated from public data by ZIP code during the peak of the pandemic in April 2020. Multivariate logistic regression was performed to identify associations with follow-up non-adherence. Results During COVID-19, 496 (68%) of 734 patients were adherent to follow-up. Of the adherent group, 40.5% had telemedicine visits. The rate of follow-up adherence during COVID-19 was dramatically lower than historic adherence rates of 89-96%, which varied depending on time since resection. On multivariate analysis, adherence was more likely among patients who had received adjuvant radiation therapy (adjusted Odds Ratio [aOR] 1.4; P = 0.032) and smokers (aOR 1.6; P = 0.041). When patients who live in The Bronx were stratified by ZIP code, there was no association (R2 = 0.01) between local COVID-19 case rates and likelihood of adherence during the COVID-19 pandemic. Conclusion To our knowledge, this is the first analysis evaluating the potential effect of COVID-19 on cancer survivorship care. We observed a dramatic disruption in long-term follow-up during the COVID-19 period, despite prevalent utilization of telemedicine visits. Overall, if the observed rate of non-adherence persists and patients are not reintegrated into regular follow-up patterns after the COVID-19 period, it has the potential to dramatically affect cancer survival outcomes.

1,050 hospitals in 44 states, a 20% stratified sample of hospitals in the US. Inclusion criteria were women with a previously specified cancer diagnosis, now hospitalized for a birth between 2015 and 2017; there were no exclusion criteria. The incidence of maternal (i.e., organ failure, infections, transfusions) and obstetric (including eclampsia, abruption, fetal distress) complications was compared between those who had / had not previously received RT. Categorical variables were compared using chi-square test. In addition, composite endpoints of 'any maternal complication' and 'any fetal complication' were analyzed, with predictors assessed using logistic regression.

Results: A total of 3215 patient hospitalizations were included in the study, of whom in 135 the mother had previous received RT. Median age − 31 years, 69% white, no sig. difference between those who did / did not receive RT. Cancer type was unevenly distributed between the two groups − RT patients had mostly lymphoma (36%), thyroid (25%) and breast (23%) cancer, whereas non-RT patients had thyroid (26%), melanoma (19%), breast (11%) and cervix (10%). Background maternal medical conditions: heart disease (OR 23.1, P < 0.001) and thyroid disease (OR 1.6, P < 0.04) were more common amongst those who had received RT. Regarding maternal medical complications, respiratory failure (OR 6.6, P < 0.01), and mechanical ventilation (OR 11.5, P = 0.01) were all more common in the 'received-RT' group. Regarding obstetric complication, none were associated with previous RT (of note, there were fewer cesarean sections in the previous RT group). On multivariate analysis for the composite endpoint 'obstetric complications' age (HR 1.02, P < 0.001), exposure to chemotherapy (HR 1.47, P = 0.01) and diabetes mellitus (HR 1.99, P = 0.06, borderline) were associated with poorer outcomes; there was no association with previous RT. On multivariate analysis for composite endpoint 'maternal complications', no single covariate was associated with a worse outcome. Conclusion: Previously RT was associated with an increased risk of maternal respiratory medical complications at time of delivery. Conversely and reassuringly, previous RT was not associated with increased fetal complications at delivery. Out data legitimize current trends to minimize cardiac radiation exposure in young women, and provide guidance for the optimal medical care of cancer survivors at time of delivery. Purpose/Objective(s): Patients who receive radiotherapy (RT) for head and neck cancer (HNC) are at risk for late radiation toxicity, recurrence, and subsequent neoplasms. Ongoing monitoring by a radiation oncologist during the survivorship period is important for detection of adverse outcomes and to guide early intervention. The purpose of this study was to identify patient level factors associated with HNC survivors becoming lost to radiation oncology follow-up care. Materials/Methods: This cross-sectional study included all surviving patients who received RT for HNC at a single comprehensive cancer center in Alabama between 2001-2018. Death records were identified using a combination of medical records and LexisNexis Accurint. Patients who had not been evaluated in the radiation oncology clinic for > 2 years were considered as lost to follow-up care. Patient level factors considered for association with becoming lost to follow-up included age (older vs. young than 65 years), distance from the clinic (more vs. less than 100 miles), median income of the zip code of residence (above vs. below median), sex, race (white vs. non-white) and time since completion of RT (more vs. fewer than 5 years). Between group differences in frequencies were assessed using the chi-square test. A classification tree was created to classify participants according to the risk of becoming lost to follow-up, with terminal nodes required to contain at least 50 patients. Results: Of the 737 patients who met the inclusion criteria, 391 (53.1%) had not been evaluated by a radiation oncologist for > 2 years. When considered individually, becoming lost to follow-up was statistically more common among patients who were > 5 years from RT (61.4% vs. 39.1%, P < 0.001), below the median income for the state of Alabama (55.8% vs. 47%, P = 0.025), and were unmarried (61.7% vs. 46.4%, P < 0.001). The first level split of the decision tree was by time from completion of RT. For patients within 5 years of completing RT, unmarried patients were more likely to be lost to follow-up (67.9% vs. 32.1%). For patients more than 5 years from completion of RT, the group consisting of both unmarried patients and married patients living > 100 miles from the clinic were more likely to be lost to follow-up (69% vs. 31%). Conclusion: This study identified time from RT, marital status, income level, and travel distance as factors associated with becoming lost to radiation oncology follow-up at an academic center in the Deep South. The decision tree supports the hypothesis that distance to the clinic may become more meaningful later in the survivorship period. Identifying factors associated with becoming lost to specialty care after cancer treatment is important for developing and targeting social support interventions for cancer survivors, particularly those with HNC who are disproportionately affected by socioeconomic disparities. 

Breast Cancer Survivorship Care During the COVID-19 Pandemic Within an Urban New York Hospital System between two and five years after breast cancer surgery. Patients were deemed adherent to follow-up during COVID-19 if they attended an oncology follow-up appointment (in-person or telemedicine) between March 1 and December 1, 2020; patients were deemed non-adherent if they attended follow-up during the same date range in 2019, prior to the pandemic, but did not follow-up during the COVID-19 period. Adherence during COVID-19 was compared with pre-COVID rates of follow-up. Clinical and demographic data were evaluated as potential predictors of adherence. Local COVID-19 case rates were estimated from public data by ZIP code during the peak of the pandemic in April 2020. Multivariate logistic regression was performed to identify associations with follow-up nonadherence. Results: During COVID-19, 496 (68%) of 734 patients were adherent to follow-up. Of the adherent group, 40.5% had telemedicine visits. The rate of follow-up adherence during COVID-19 was dramatically lower than historic adherence rates of 89-96%, which varied depending on time since resection. On multivariate analysis, adherence was more likely among patients who had received adjuvant radiation therapy (adjusted Odds Ratio [aOR] 1.4; P = 0.032) and smokers (aOR 1.6; P = 0.041). When patients who live in The Bronx were stratified by ZIP code, there was no association (R 2 = 0.01) between local COVID-19 case rates and likelihood of adherence during the COVID-19 pandemic. Conclusion: To our knowledge, this is the first analysis evaluating the potential effect of COVID-19 on cancer survivorship care. We observed a dramatic disruption in long-term follow-up during the COVID-19 period, despite prevalent utilization of telemedicine visits. Overall, if the observed rate of non-adherence persists and patients are not reintegrated into regular follow-up patterns after the COVID-19 period, it has the potential to dramatically affect cancer survival outcomes. Purpose/Objective(s): Cancer patients are at elevated risk of suicide due to additional disease-specific factors relating to cancer and its treatments. Given that cancer survivorship in the United States continues to improve, evaluating the risk and identifying factors associated with suicide among cancer survivors is warranted. Materials/Methods: This population-based study examined the National Center for Health Statistics Multiple-Cause Mortality data for adult cancer survivors aged ≥ 20 with suicide and self-inflicted injury as the underlying cause and malignant neoplasm as a contributing cause of death. Associations with death by suicide were assessed with multivariable logistic regression for demographic and comorbid factors, and univariate logistic regression for anatomic site of cancer stratified by sex. Trends in suicide rates of non-cancer and cancer survivors were assessed with Pearson's correlation coefficient. (Table) . Over the study period, the suicide rate of those without a history of cancer increased (r = 0.95, P < .0005) while the overall suicide rate of cancer survivors decreased (r = -0.60, P = 0.005). Specifically, suicide rates decreased for thoracic, gastrointestinal, genitourinary, and head and neck cancers, with the largest decline in multiple, metastatic, not otherwise specified sites (r = -0.67, P = 0.001). Conclusion: Among adult cancer survivors, suicide risk varies with sociodemographic status, comorbid conditions, and anatomic cancer site. Although the suicide rate of cancer survivors has declined overall, further research is needed to develop interventions in high-risk cancer patients, particularly those with a history of depression, to mitigate suicide risk and improve survivorship care.

Abstract 2318 − Table 1 Female Male 

Research Grant; National Institutes of Health, American Cancer Society. C. Tsai: Honoraria

Second Cancer Risk in Childhood Cancer Survivors Treated with Intensity-Modulated Radiation Therapy (IMRT): An Updated Analysis of More Than 10 Years of Follow

United States Purpose/Objective(s): It is unclear how treatment with intensity-modulated radiation therapy (IMRT) impacts long-term risk of second malignant neoplasms (SMNs) in pediatric patients. A preliminary report from our institution published in 2015 by Casey et al

and who survived with follow-up data > = 5 years after IMRT were included. The total dose of IMRT to any field was calculated and adjusted for contribution of conventional radiotherapy. Exposure to chemotherapy was recorded and noted if exposed to alkylating agents, anthracyclines, and/or epidodophyllotoxins. Treatment plans were evaluated to assess whether SMNs occurred within the treatment field. CI estimates of all SMN and second solid malignancies were calculated using the CI method of competing risks with death considered a competing event. Results: A total of 326 patients were included with a median follow-up of 11 years from IMRT initiation (IQR, 8.6-14.0). The most common primary diagnosis was soft tissue sarcoma (n = 109, 33.4%) followed by neuroblastoma (n = 64, 19.6%). Most (n = 282, 86.5%) received chemotherapy